For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital

About this trial

Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable "one-stop" solution for treating heart attack patients who have multiple blocked arteries. Currently, doctors face a dilemma: Testing these other blockages during the heart attack procedure is often unreliable.

The most accurate method requires asking the patient to return 30 days later for a second invasive procedure, which is a significant burden.

The Study's Hypothesis : We are testing a new tool called UFR, which uses ultrasound images to measure blockages. Our hypothesis (or "educated guess") is that this new UFR tool is not affected by the body's stress during a heart attack and can provide a true, reliable measurement right away.

The Question the Study is Trying to Answer : The main question this study is trying to answer is: Can the new "one-stop" UFR tool, used during the initial heart attack procedure, accurately predict which blockages are truly serious... thereby eliminating the need for patients to return for a second procedure 30 days later? Researchers will also follow 200 patients for one year, using advanced scans (like UFR, standard tests, and MRI), to better understand how the heart and arteries heal and change over time.

Eligibility criteria

Qualifiers

Age >18 years, any sex.

The participant is able to understand the study procedures and provides voluntary written informed consent.

STEMI Cohort: Symptom onset < 12 hours with ECG findings of ST-segment elevation myocardial infarction.

High-Risk NSTEMI Cohort: Meets at least one of the following: GRACE score > 140, dynamic ECG changes (ST-T), or significant Troponin elevation.

Disqualifiers

Presence of cardiogenic shock on presentation, or persistent hemodynamic instability despite successful PCI of the culprit vessel.

Known severe allergy to iodinated contrast media or gadolinium-based contrast agents (used for CMR).

Female participants who are pregnant, breastfeeding, or planning pregnancy within the 1-year study period.Unprotected left main coronary artery disease (stenosis <50%) requiring intervention.

Prior history of Coronary Artery Bypass Grafting (CABG) surgery.The target NCV has received prior PCI (e.g., existing stent) or surgical revascularization.

Trial design

Treatments tested in this trial

  • IVUS-based Fractional Flow Reserve (UFR)
  • Invasive Coronary Physiology Measurement (FFR/RFR/IMR)
  • Cardiac Magnetic Resonance (CMR)

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators